lapatinib has been researched along with Cell Transformation, Neoplastic in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Athanasiadis, E; Chalari, A; Chavdoula, E; Kafalidou, A; Klinakis, A; Konstantopoulos, D; Melissa, P; Papafotiou, G; Paschalidis, N; Pateras, IS; Simigdala, N; Sklirou, AD; Trougakos, IP | 1 |
| Boakye-Agyeman, F; Boughey, JC; Dai, Q; Goetz, MP; Hitosugi, S; Hitosugi, T; Karnitz, LM; Kaufmann, SH; Kurmi, K; Larson, TR; Lou, Z; Machida, YJ; Wang, L; Wiese, EK; Yu, J | 1 |
| Fan, YX; Johnson, GR; Marino, MP; Ou, W; Reiser, J; Shen, Y; Wong, KK; Wong, L; Wu, WJ | 1 |
| Barker, HE; Chang, J; Cox, TR; Erler, JT; Martens, JW; Nicolau, MM; Wetterskog, D | 1 |
| Agrawal, NS; Cronin, JC; Cruz, P; Lin, JC; Prickett, TD; Rosenberg, SA; Samuels, Y; Wei, X; Wunderlich, JR; Yates, KE | 1 |
| Ansaldi, F; Bagnasco, L; Ballestrero, A; Cea, M; Cirmena, G; Garuti, A; Grillo, V; Icardi, G; Moran, E; Nencioni, A; Parodi, S; Patrone, F; Rocco, I; Soncini, D; Zoppoli, G | 1 |
| Durbin, JE; Koromilas, AE; Muller, WJ; Raven, JF; Tremblay, ML; Wang, S; Williams, V | 1 |
| Berlin, JD; Lockhart, AC; Lockhart, C | 1 |
| Boukouvala, S; Calkins, K; Cutler, RE; Fong, R; Funke, R; Gendreau, SB; Gerritsen, ME; Heuer, TS; Kim, YD; Lamb, P; Matthews, DJ; Miller, N; Trowe, T; Vysotskaia, V; Woolfrey, JR; Yang, JP | 1 |
1 review(s) available for lapatinib and Cell Transformation, Neoplastic
| Article | Year |
|---|---|
The epidermal growth factor receptor as a target for colorectal cancer therapy.
Topics: Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Transformation, Neoplastic; Cetuximab; Colorectal Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Organic Chemicals; Panitumumab; Prognosis; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction | 2005 |
8 other study(ies) available for lapatinib and Cell Transformation, Neoplastic
| Article | Year |
|---|---|
Loss of Kmt2c in vivo leads to EMT, mitochondrial dysfunction and improved response to lapatinib in breast cancer.
Topics: Animals; Breast Neoplasms; Cell Transformation, Neoplastic; DNA-Binding Proteins; Epithelial-Mesenchymal Transition; Female; Genes, Tumor Suppressor; Humans; Lapatinib; Mice; Mice, Knockout; Mitochondria | 2023 |
Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; Creatine Kinase; Creatinine; Drug Resistance, Neoplasm; Energy Metabolism; Energy Transfer; Female; Gene Knockdown Techniques; Humans; Lapatinib; Mice; Mice, Nude; Mitochondria; Mitochondrial Proteins; Phosphocreatine; Phosphorylation; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2018 |
Acquired substrate preference for GAB1 protein bestows transforming activity to ERBB2 kinase lung cancer mutants.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphate; Amino Acid Substitution; Animals; Antineoplastic Agents; Cell Transformation, Neoplastic; Female; Humans; Lapatinib; Lung Neoplasms; Mice; Mice, Nude; Mice, Transgenic; Mutation, Missense; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Quinazolines; Receptor, ErbB-2; Signal Transduction; Substrate Specificity | 2013 |
LOXL2 induces aberrant acinar morphogenesis via ErbB2 signaling.
Topics: Acinar Cells; Amino Acid Oxidoreductases; Breast Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; Epithelial Cells; Epithelial-Mesenchymal Transition; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mammary Glands, Human; Morphogenesis; Neoplasm Metastasis; Phenotype; Prognosis; Quinazolines; Reactive Oxygen Species; Receptor, ErbB-2; Signal Transduction | 2013 |
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Proliferation; Cell Transformation, Neoplastic; ErbB Receptors; Humans; Lapatinib; Melanoma; Mice; Mutation; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-4; RNA Interference; Skin Neoplasms | 2009 |
Ras-induced resistance to lapatinib is overcome by MEK inhibition.
Topics: Antineoplastic Agents; Breast Neoplasms; Butadienes; Cell Line, Tumor; Cell Survival; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Genes, ras; Humans; Immunoblotting; Lapatinib; Mitogen-Activated Protein Kinase Kinases; Mutation; Nitriles; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2010 |
Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Transformation, Neoplastic; Chlorocebus aethiops; Disease Progression; Female; Gefitinib; Humans; Lapatinib; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Phosphorylation; Quinazolines; Receptor, ErbB-2; Signal Transduction; STAT1 Transcription Factor; Transplantation, Heterologous | 2011 |
EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.
Topics: Antineoplastic Agents; Cell Survival; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Humans; Lapatinib; Mutation; Phosphorylation; Protein Conformation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2008 |